Date | Time | Source | Headline | Symbol | Company |
05/06/2024 | 2:00AM | GlobeNewswire Inc. | Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca | NASDAQ:AZN | AstraZeneca PLC |
05/02/2024 | 7:00AM | Business Wire | CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
05/01/2024 | 7:05AM | Business Wire | AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio | NASDAQ:AZN | AstraZeneca PLC |
04/29/2024 | 7:00AM | Business Wire | ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow | NASDAQ:AZN | AstraZeneca PLC |
04/25/2024 | 8:00AM | PR Newswire (US) | AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | NASDAQ:AZN | AstraZeneca PLC |
04/25/2024 | 7:53AM | IH Market News | U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast | NASDAQ:AZN | AstraZeneca PLC |
04/25/2024 | 7:52AM | IH Market News | Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings | NASDAQ:AZN | AstraZeneca PLC |
04/25/2024 | 2:00AM | Business Wire | Q1 2024 results | NASDAQ:AZN | AstraZeneca PLC |
04/16/2024 | 7:00AM | Business Wire | IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
04/12/2024 | 7:05AM | IH Market News | Paramount Global Board Shrinks, Morgan Stanley Faces Regulatory Probe, and More News | NASDAQ:AZN | AstraZeneca PLC |
04/11/2024 | 7:24AM | IH Market News | Costco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More News | NASDAQ:AZN | AstraZeneca PLC |
04/11/2024 | 7:00AM | Business Wire | FASENRA approved for treatment of children aged 6 to 11 with severe asthma | NASDAQ:AZN | AstraZeneca PLC |
04/05/2024 | 11:10PM | Business Wire | ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors | NASDAQ:AZN | AstraZeneca PLC |
04/05/2024 | 9:43PM | Business Wire | ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors | NASDAQ:AZN | AstraZeneca PLC |
04/05/2024 | 7:00AM | Business Wire | IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial | NASDAQ:AZN | AstraZeneca PLC |
04/02/2024 | 7:00AM | Business Wire | Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer | NASDAQ:AZN | AstraZeneca PLC |
04/02/2024 | 2:00AM | Business Wire | Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer | NASDAQ:AZN | AstraZeneca PLC |
04/01/2024 | 7:00AM | Business Wire | VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH | NASDAQ:AZN | AstraZeneca PLC |
03/27/2024 | 6:54AM | IH Market News | GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News | NASDAQ:AZN | AstraZeneca PLC |
03/26/2024 | 7:20AM | IH Market News | Super Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest News | NASDAQ:AZN | AstraZeneca PLC |
03/25/2024 | 7:00AM | Business Wire | ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) | NASDAQ:AZN | AstraZeneca PLC |
03/19/2024 | 7:33AM | IH Market News | Unilever Initiates Ice Cream Division Spin-Off and Announces Job Cuts; Berkshire Ramps Up Share Buyback Efforts, and More | NASDAQ:AZN | AstraZeneca PLC |
03/19/2024 | 7:00AM | Business Wire | AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer | NASDAQ:AZN | AstraZeneca PLC |
03/19/2024 | 6:52AM | IH Market News | AstraZeneca to acquire Fusion for $2 billion | NASDAQ:AZN | AstraZeneca PLC |
03/18/2024 | 7:00AM | Business Wire | AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio | NASDAQ:AZN | AstraZeneca PLC |
03/14/2024 | 7:39AM | IH Market News | Fisker’s Shares Take a Hit Amid Speculation of Bankruptcy, Altria Divests from AB InBev to Fund Stock Repurchase Initiative | NASDAQ:AZN | AstraZeneca PLC |
03/13/2024 | 7:06AM | Business Wire | AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD | NASDAQ:AZN | AstraZeneca PLC |
03/07/2024 | 5:43AM | IH Market News | Tesla Exits Market Top 10, Victoria’s Secret Stock Tumbles 30% on Weak Forecast | NASDAQ:AZN | AstraZeneca PLC |
02/26/2024 | 4:05PM | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:AZN | AstraZeneca PLC |
02/26/2024 | 9:00AM | PR Newswire (Canada) | Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE Campaign | NASDAQ:AZN | AstraZeneca PLC |